# Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

> **NCT01778413** · PHASE4 · COMPLETED · sponsor: **Anna Cruceta** · enrollment: 61 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** ATRIPLA

## Key facts

- **NCT ID:** NCT01778413
- **Lead sponsor:** Anna Cruceta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-03
- **Primary completion:** 2014-11-14
- **Final completion:** 2015-07-21
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01778413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01778413, "Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01778413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*